A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice.

ABSTRACT: Influenza virus infections pose a significant threat to global health. Vaccination is the main countermeasure against influenza virus spread, however, the effectiveness of vaccines is variable. Current seasonal influenza virus vaccines mostly rely on the immunodominant hemagglutinin (HA) glycoprotein on the viral surface, which usually leads to a narrow and strain-specific immune response. The HA undergoes constant antigenic drift, which can lead to a dramatic loss in vaccine effectiveness, requiring the annual reformulation and readministration of influenza virus vaccines. Recently, it has been demonstrated that the subdominant glycoprotein, neuraminidase (NA), is an attractive target for vaccine development. Here, we tested a newly developed recombinant influenza virus N1 neuraminidase v

SUBMITTER: Strohmeier S 

PROVIDER: S-EPMC9305062 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature